nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR3—germ cell cancer	0.359	0.69	CbGaD
Ponatinib—KIT—germ cell cancer	0.161	0.31	CbGaD
Ponatinib—ABCB11—Vinblastine—germ cell cancer	0.0378	0.174	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—germ cell cancer	0.0287	0.132	CbGbCtD
Ponatinib—CYP3A5—Ifosfamide—germ cell cancer	0.0188	0.0863	CbGbCtD
Ponatinib—CYP2C8—Ifosfamide—germ cell cancer	0.0181	0.083	CbGbCtD
Ponatinib—ABCG2—Cisplatin—germ cell cancer	0.0165	0.0758	CbGbCtD
Ponatinib—ABCG2—Etoposide—germ cell cancer	0.0162	0.0744	CbGbCtD
Ponatinib—ABCG2—Methotrexate—germ cell cancer	0.0107	0.0492	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—germ cell cancer	0.0104	0.0476	CbGbCtD
Ponatinib—CYP3A5—Etoposide—germ cell cancer	0.00898	0.0412	CbGbCtD
Ponatinib—CYP2C8—Etoposide—germ cell cancer	0.00863	0.0396	CbGbCtD
Ponatinib—CYP3A4—Ifosfamide—germ cell cancer	0.00732	0.0336	CbGbCtD
Ponatinib—ABCB1—Vinblastine—germ cell cancer	0.00648	0.0298	CbGbCtD
Ponatinib—CYP2D6—Vinblastine—germ cell cancer	0.00611	0.0281	CbGbCtD
Ponatinib—ABCB1—Cisplatin—germ cell cancer	0.00595	0.0273	CbGbCtD
Ponatinib—ABCB1—Etoposide—germ cell cancer	0.00584	0.0268	CbGbCtD
Ponatinib—CYP3A4—Vinblastine—germ cell cancer	0.00389	0.0178	CbGbCtD
Ponatinib—ABCB1—Methotrexate—germ cell cancer	0.00386	0.0177	CbGbCtD
Ponatinib—CYP3A4—Etoposide—germ cell cancer	0.0035	0.0161	CbGbCtD
Ponatinib—FGFR4—Podofilox—Etoposide—germ cell cancer	0.00221	1	CbGdCrCtD
Ponatinib—Nilotinib—KIT—germ cell cancer	0.00142	0.545	CrCbGaD
Ponatinib—Imatinib—KIT—germ cell cancer	0.00119	0.455	CrCbGaD
Ponatinib—FGFR2—embryo—germ cell cancer	0.000352	0.00474	CbGeAlD
Ponatinib—TEK—trigeminal ganglion—germ cell cancer	0.000349	0.0047	CbGeAlD
Ponatinib—FGFR3—medulla oblongata—germ cell cancer	0.000343	0.00462	CbGeAlD
Ponatinib—TEK—embryo—germ cell cancer	0.000337	0.00454	CbGeAlD
Ponatinib—FGFR1—telencephalon—germ cell cancer	0.000336	0.00453	CbGeAlD
Ponatinib—KDR—neck—germ cell cancer	0.000331	0.00445	CbGeAlD
Ponatinib—FGFR2—brainstem—germ cell cancer	0.000322	0.00434	CbGeAlD
Ponatinib—FGFR1—decidua—germ cell cancer	0.000319	0.00429	CbGeAlD
Ponatinib—FGFR3—adrenal gland—germ cell cancer	0.000318	0.00428	CbGeAlD
Ponatinib—BCR—gonad—germ cell cancer	0.000316	0.00425	CbGeAlD
Ponatinib—FGFR3—midbrain—germ cell cancer	0.000314	0.00423	CbGeAlD
Ponatinib—FGFR2—eye—germ cell cancer	0.000314	0.00423	CbGeAlD
Ponatinib—BCR—uterus—germ cell cancer	0.000314	0.00422	CbGeAlD
Ponatinib—FLT3—gonad—germ cell cancer	0.000313	0.00422	CbGeAlD
Ponatinib—BCR—pituitary gland—germ cell cancer	0.000308	0.00415	CbGeAlD
Ponatinib—FGFR3—spinal cord—germ cell cancer	0.000306	0.00412	CbGeAlD
Ponatinib—PDGFRA—embryo—germ cell cancer	0.000306	0.00411	CbGeAlD
Ponatinib—SRC—embryo—germ cell cancer	0.0003	0.00404	CbGeAlD
Ponatinib—BCR—medulla oblongata—germ cell cancer	0.000297	0.004	CbGeAlD
Ponatinib—KIT—neck—germ cell cancer	0.000293	0.00394	CbGeAlD
Ponatinib—FGFR4—brain—germ cell cancer	0.000289	0.00389	CbGeAlD
Ponatinib—CYP3A4—urine—germ cell cancer	0.000289	0.00389	CbGeAlD
Ponatinib—FGFR2—telencephalon—germ cell cancer	0.000286	0.00385	CbGeAlD
Ponatinib—KDR—trigeminal ganglion—germ cell cancer	0.000285	0.00384	CbGeAlD
Ponatinib—RET—decidua—germ cell cancer	0.000285	0.00384	CbGeAlD
Ponatinib—LCK—decidua—germ cell cancer	0.000285	0.00384	CbGeAlD
Ponatinib—CYP2D6—urine—germ cell cancer	0.000284	0.00383	CbGeAlD
Ponatinib—FGFR4—lymph node—germ cell cancer	0.000279	0.00376	CbGeAlD
Ponatinib—FGFR1—uterus—germ cell cancer	0.000279	0.00376	CbGeAlD
Ponatinib—LYN—endocrine gland—germ cell cancer	0.000277	0.00373	CbGeAlD
Ponatinib—FGFR3—endocrine gland—germ cell cancer	0.000276	0.00371	CbGeAlD
Ponatinib—KDR—embryo—germ cell cancer	0.000276	0.00371	CbGeAlD
Ponatinib—BCR—adrenal gland—germ cell cancer	0.000275	0.0037	CbGeAlD
Ponatinib—TEK—telencephalon—germ cell cancer	0.000274	0.00369	CbGeAlD
Ponatinib—FGFR1—pituitary gland—germ cell cancer	0.000274	0.00369	CbGeAlD
Ponatinib—LYN—head—germ cell cancer	0.000274	0.00368	CbGeAlD
Ponatinib—FLT3—adrenal gland—germ cell cancer	0.000273	0.00368	CbGeAlD
Ponatinib—FGFR2—skin of body—germ cell cancer	0.000273	0.00368	CbGeAlD
Ponatinib—FGFR3—head—germ cell cancer	0.000272	0.00366	CbGeAlD
Ponatinib—BCR—midbrain—germ cell cancer	0.000272	0.00366	CbGeAlD
Ponatinib—SRC—eye—germ cell cancer	0.000267	0.0036	CbGeAlD
Ponatinib—BCR—bone marrow—germ cell cancer	0.000266	0.00358	CbGeAlD
Ponatinib—BCR—spinal cord—germ cell cancer	0.000265	0.00357	CbGeAlD
Ponatinib—SRC—retina—germ cell cancer	0.000265	0.00357	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—germ cell cancer	0.000264	0.00356	CbGeAlD
Ponatinib—FLT3—bone marrow—germ cell cancer	0.000264	0.00356	CbGeAlD
Ponatinib—FGFR3—testis—germ cell cancer	0.000263	0.00354	CbGeAlD
Ponatinib—TEK—decidua—germ cell cancer	0.00026	0.0035	CbGeAlD
Ponatinib—BCR—female gonad—germ cell cancer	0.000256	0.00345	CbGeAlD
Ponatinib—FLT3—female gonad—germ cell cancer	0.000255	0.00343	CbGeAlD
Ponatinib—KIT—trigeminal ganglion—germ cell cancer	0.000253	0.00341	CbGeAlD
Ponatinib—LCK—uterus—germ cell cancer	0.00025	0.00336	CbGeAlD
Ponatinib—PDGFRA—telencephalon—germ cell cancer	0.000248	0.00335	CbGeAlD
Ponatinib—KDR—eye—germ cell cancer	0.000246	0.00331	CbGeAlD
Ponatinib—RET—pituitary gland—germ cell cancer	0.000245	0.0033	CbGeAlD
Ponatinib—FGFR1—adrenal gland—germ cell cancer	0.000245	0.0033	CbGeAlD
Ponatinib—KIT—embryo—germ cell cancer	0.000244	0.00329	CbGeAlD
Ponatinib—KDR—retina—germ cell cancer	0.000244	0.00328	CbGeAlD
Ponatinib—SRC—telencephalon—germ cell cancer	0.000244	0.00328	CbGeAlD
Ponatinib—FGFR3—cerebellum—germ cell cancer	0.000243	0.00327	CbGeAlD
Ponatinib—FGFR1—midbrain—germ cell cancer	0.000242	0.00325	CbGeAlD
Ponatinib—BCR—endocrine gland—germ cell cancer	0.000239	0.00321	CbGeAlD
Ponatinib—FGFR2—uterus—germ cell cancer	0.000237	0.00319	CbGeAlD
Ponatinib—FLT3—endocrine gland—germ cell cancer	0.000237	0.00319	CbGeAlD
Ponatinib—RET—medulla oblongata—germ cell cancer	0.000237	0.00319	CbGeAlD
Ponatinib—FGFR1—spinal cord—germ cell cancer	0.000236	0.00317	CbGeAlD
Ponatinib—PDGFRA—decidua—germ cell cancer	0.000236	0.00317	CbGeAlD
Ponatinib—BCR—head—germ cell cancer	0.000235	0.00317	CbGeAlD
Ponatinib—SRC—skin of body—germ cell cancer	0.000233	0.00313	CbGeAlD
Ponatinib—SRC—decidua—germ cell cancer	0.000231	0.00311	CbGeAlD
Ponatinib—FGFR1—female gonad—germ cell cancer	0.000228	0.00307	CbGeAlD
Ponatinib—BCR—testis—germ cell cancer	0.000227	0.00306	CbGeAlD
Ponatinib—TEK—uterus—germ cell cancer	0.000227	0.00306	CbGeAlD
Ponatinib—FLT3—testis—germ cell cancer	0.000226	0.00304	CbGeAlD
Ponatinib—KIT—brainstem—germ cell cancer	0.000224	0.00301	CbGeAlD
Ponatinib—TEK—pituitary gland—germ cell cancer	0.000223	0.00301	CbGeAlD
Ponatinib—ABL1—trigeminal ganglion—germ cell cancer	0.00022	0.00297	CbGeAlD
Ponatinib—RET—adrenal gland—germ cell cancer	0.000219	0.00295	CbGeAlD
Ponatinib—LCK—adrenal gland—germ cell cancer	0.000219	0.00295	CbGeAlD
Ponatinib—RET—midbrain—germ cell cancer	0.000216	0.00291	CbGeAlD
Ponatinib—TEK—medulla oblongata—germ cell cancer	0.000215	0.0029	CbGeAlD
Ponatinib—ABL1—embryo—germ cell cancer	0.000213	0.00286	CbGeAlD
Ponatinib—KDR—decidua—germ cell cancer	0.000212	0.00286	CbGeAlD
Ponatinib—LCK—bone marrow—germ cell cancer	0.000212	0.00285	CbGeAlD
Ponatinib—RET—spinal cord—germ cell cancer	0.000211	0.00284	CbGeAlD
Ponatinib—BCR—cerebellum—germ cell cancer	0.00021	0.00283	CbGeAlD
Ponatinib—FLT3—cerebellum—germ cell cancer	0.000209	0.00281	CbGeAlD
Ponatinib—FGFR2—adrenal gland—germ cell cancer	0.000208	0.0028	CbGeAlD
Ponatinib—PDGFRA—gonad—germ cell cancer	0.000207	0.00279	CbGeAlD
Ponatinib—PDGFRA—uterus—germ cell cancer	0.000206	0.00277	CbGeAlD
Ponatinib—LCK—female gonad—germ cell cancer	0.000204	0.00275	CbGeAlD
Ponatinib—SRC—gonad—germ cell cancer	0.000203	0.00274	CbGeAlD
Ponatinib—FGFR1—testis—germ cell cancer	0.000202	0.00273	CbGeAlD
Ponatinib—FGFR2—spinal cord—germ cell cancer	0.0002	0.0027	CbGeAlD
Ponatinib—TEK—adrenal gland—germ cell cancer	0.000199	0.00269	CbGeAlD
Ponatinib—KIT—telencephalon—germ cell cancer	0.000199	0.00268	CbGeAlD
Ponatinib—LYN—brain—germ cell cancer	0.000198	0.00267	CbGeAlD
Ponatinib—FGFR3—brain—germ cell cancer	0.000197	0.00266	CbGeAlD
Ponatinib—TEK—midbrain—germ cell cancer	0.000197	0.00265	CbGeAlD
Ponatinib—ABL1—brainstem—germ cell cancer	0.000195	0.00262	CbGeAlD
Ponatinib—FGFR2—female gonad—germ cell cancer	0.000194	0.00261	CbGeAlD
Ponatinib—TEK—spinal cord—germ cell cancer	0.000192	0.00259	CbGeAlD
Ponatinib—RET—endocrine gland—germ cell cancer	0.00019	0.00256	CbGeAlD
Ponatinib—ABL1—eye—germ cell cancer	0.00019	0.00255	CbGeAlD
Ponatinib—KIT—skin of body—germ cell cancer	0.00019	0.00255	CbGeAlD
Ponatinib—KIT—decidua—germ cell cancer	0.000188	0.00254	CbGeAlD
Ponatinib—ABL1—retina—germ cell cancer	0.000188	0.00253	CbGeAlD
Ponatinib—RET—head—germ cell cancer	0.000187	0.00252	CbGeAlD
Ponatinib—FGFR1—cerebellum—germ cell cancer	0.000187	0.00252	CbGeAlD
Ponatinib—TEK—female gonad—germ cell cancer	0.000186	0.00251	CbGeAlD
Ponatinib—KDR—uterus—germ cell cancer	0.000186	0.0025	CbGeAlD
Ponatinib—ABCB11—endocrine gland—germ cell cancer	0.000185	0.0025	CbGeAlD
Ponatinib—KDR—pituitary gland—germ cell cancer	0.000183	0.00246	CbGeAlD
Ponatinib—LCK—testis—germ cell cancer	0.000181	0.00244	CbGeAlD
Ponatinib—RET—testis—germ cell cancer	0.000181	0.00244	CbGeAlD
Ponatinib—PDGFRA—adrenal gland—germ cell cancer	0.000181	0.00243	CbGeAlD
Ponatinib—FGFR2—endocrine gland—germ cell cancer	0.00018	0.00243	CbGeAlD
Ponatinib—FGFR2—head—germ cell cancer	0.000178	0.0024	CbGeAlD
Ponatinib—SRC—adrenal gland—germ cell cancer	0.000177	0.00239	CbGeAlD
Ponatinib—ABCB11—testis—germ cell cancer	0.000177	0.00238	CbGeAlD
Ponatinib—KDR—medulla oblongata—germ cell cancer	0.000176	0.00237	CbGeAlD
Ponatinib—PDGFRA—spinal cord—germ cell cancer	0.000174	0.00234	CbGeAlD
Ponatinib—TEK—endocrine gland—germ cell cancer	0.000173	0.00233	CbGeAlD
Ponatinib—ABL1—telencephalon—germ cell cancer	0.000173	0.00233	CbGeAlD
Ponatinib—FGFR2—testis—germ cell cancer	0.000172	0.00232	CbGeAlD
Ponatinib—TEK—head—germ cell cancer	0.000171	0.0023	CbGeAlD
Ponatinib—SRC—spinal cord—germ cell cancer	0.000171	0.0023	CbGeAlD
Ponatinib—BCR—brain—germ cell cancer	0.000171	0.0023	CbGeAlD
Ponatinib—PDGFRA—female gonad—germ cell cancer	0.000169	0.00227	CbGeAlD
Ponatinib—RET—cerebellum—germ cell cancer	0.000167	0.00225	CbGeAlD
Ponatinib—KIT—gonad—germ cell cancer	0.000166	0.00223	CbGeAlD
Ponatinib—SRC—female gonad—germ cell cancer	0.000165	0.00223	CbGeAlD
Ponatinib—ABL1—skin of body—germ cell cancer	0.000165	0.00222	CbGeAlD
Ponatinib—TEK—testis—germ cell cancer	0.000165	0.00222	CbGeAlD
Ponatinib—BCR—lymph node—germ cell cancer	0.000165	0.00222	CbGeAlD
Ponatinib—KIT—uterus—germ cell cancer	0.000165	0.00222	CbGeAlD
Ponatinib—ABL1—decidua—germ cell cancer	0.000164	0.00221	CbGeAlD
Ponatinib—FLT3—lymph node—germ cell cancer	0.000164	0.0022	CbGeAlD
Ponatinib—KDR—adrenal gland—germ cell cancer	0.000163	0.0022	CbGeAlD
Ponatinib—KIT—pituitary gland—germ cell cancer	0.000162	0.00218	CbGeAlD
Ponatinib—KDR—midbrain—germ cell cancer	0.000161	0.00217	CbGeAlD
Ponatinib—FGFR2—cerebellum—germ cell cancer	0.000159	0.00214	CbGeAlD
Ponatinib—KDR—bone marrow—germ cell cancer	0.000158	0.00212	CbGeAlD
Ponatinib—KDR—spinal cord—germ cell cancer	0.000157	0.00212	CbGeAlD
Ponatinib—PDGFRA—endocrine gland—germ cell cancer	0.000157	0.00211	CbGeAlD
Ponatinib—KIT—medulla oblongata—germ cell cancer	0.000156	0.0021	CbGeAlD
Ponatinib—Blood uric acid increased—Methotrexate—germ cell cancer	0.000156	0.00195	CcSEcCtD
Ponatinib—PDGFRA—head—germ cell cancer	0.000155	0.00208	CbGeAlD
Ponatinib—Erythema—Dactinomycin—germ cell cancer	0.000154	0.00193	CcSEcCtD
Ponatinib—SRC—endocrine gland—germ cell cancer	0.000154	0.00207	CbGeAlD
Ponatinib—Acute coronary syndrome—Cisplatin—germ cell cancer	0.000154	0.00193	CcSEcCtD
Ponatinib—Pulmonary embolism—Methotrexate—germ cell cancer	0.000153	0.00192	CcSEcCtD
Ponatinib—Anaemia—Bleomycin—germ cell cancer	0.000153	0.00192	CcSEcCtD
Ponatinib—Neuropathy peripheral—Cisplatin—germ cell cancer	0.000153	0.00192	CcSEcCtD
Ponatinib—Myocardial infarction—Cisplatin—germ cell cancer	0.000153	0.00192	CcSEcCtD
Ponatinib—TEK—cerebellum—germ cell cancer	0.000152	0.00205	CbGeAlD
Ponatinib—Pancytopenia—Etoposide—germ cell cancer	0.000152	0.00191	CcSEcCtD
Ponatinib—KDR—female gonad—germ cell cancer	0.000152	0.00205	CbGeAlD
Ponatinib—Stomatitis—Cisplatin—germ cell cancer	0.000152	0.00191	CcSEcCtD
Ponatinib—FGFR1—brain—germ cell cancer	0.000152	0.00204	CbGeAlD
Ponatinib—SRC—head—germ cell cancer	0.000152	0.00204	CbGeAlD
Ponatinib—Eye disorder—Ifosfamide—germ cell cancer	0.000152	0.0019	CcSEcCtD
Ponatinib—Flushing—Ifosfamide—germ cell cancer	0.000151	0.00189	CcSEcCtD
Ponatinib—Cardiac disorder—Ifosfamide—germ cell cancer	0.000151	0.00189	CcSEcCtD
Ponatinib—Neutropenia—Etoposide—germ cell cancer	0.00015	0.00188	CcSEcCtD
Ponatinib—PDGFRA—testis—germ cell cancer	0.000149	0.00201	CbGeAlD
Ponatinib—Leukopenia—Bleomycin—germ cell cancer	0.000148	0.00186	CcSEcCtD
Ponatinib—Hepatobiliary disease—Cisplatin—germ cell cancer	0.000147	0.00185	CcSEcCtD
Ponatinib—Angiopathy—Ifosfamide—germ cell cancer	0.000147	0.00185	CcSEcCtD
Ponatinib—FGFR1—lymph node—germ cell cancer	0.000147	0.00198	CbGeAlD
Ponatinib—SRC—testis—germ cell cancer	0.000147	0.00197	CbGeAlD
Ponatinib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.000146	0.00183	CcSEcCtD
Ponatinib—Skin exfoliation—Methotrexate—germ cell cancer	0.000146	0.00183	CcSEcCtD
Ponatinib—Chills—Ifosfamide—germ cell cancer	0.000146	0.00183	CcSEcCtD
Ponatinib—Arrhythmia—Ifosfamide—germ cell cancer	0.000145	0.00182	CcSEcCtD
Ponatinib—KIT—adrenal gland—germ cell cancer	0.000144	0.00195	CbGeAlD
Ponatinib—ABL1—gonad—germ cell cancer	0.000144	0.00194	CbGeAlD
Ponatinib—Cough—Bleomycin—germ cell cancer	0.000144	0.00181	CcSEcCtD
Ponatinib—Pneumonia—Etoposide—germ cell cancer	0.000144	0.0018	CcSEcCtD
Ponatinib—Paraesthesia—Vinblastine—germ cell cancer	0.000143	0.0018	CcSEcCtD
Ponatinib—ABL1—uterus—germ cell cancer	0.000143	0.00193	CbGeAlD
Ponatinib—Alopecia—Ifosfamide—germ cell cancer	0.000143	0.0018	CcSEcCtD
Ponatinib—Infestation—Etoposide—germ cell cancer	0.000143	0.00179	CcSEcCtD
Ponatinib—Infestation NOS—Etoposide—germ cell cancer	0.000143	0.00179	CcSEcCtD
Ponatinib—KIT—midbrain—germ cell cancer	0.000143	0.00192	CbGeAlD
Ponatinib—Anaemia—Dactinomycin—germ cell cancer	0.000142	0.00179	CcSEcCtD
Ponatinib—Mental disorder—Ifosfamide—germ cell cancer	0.000142	0.00178	CcSEcCtD
Ponatinib—KDR—endocrine gland—germ cell cancer	0.000141	0.0019	CbGeAlD
Ponatinib—Malnutrition—Ifosfamide—germ cell cancer	0.000141	0.00177	CcSEcCtD
Ponatinib—Erythema—Ifosfamide—germ cell cancer	0.000141	0.00177	CcSEcCtD
Ponatinib—ABL1—pituitary gland—germ cell cancer	0.000141	0.0019	CbGeAlD
Ponatinib—Acute coronary syndrome—Etoposide—germ cell cancer	0.000141	0.00177	CcSEcCtD
Ponatinib—Myalgia—Bleomycin—germ cell cancer	0.000141	0.00176	CcSEcCtD
Ponatinib—Myocardial infarction—Etoposide—germ cell cancer	0.00014	0.00176	CcSEcCtD
Ponatinib—Neuropathy peripheral—Etoposide—germ cell cancer	0.00014	0.00176	CcSEcCtD
Ponatinib—KIT—bone marrow—germ cell cancer	0.00014	0.00188	CbGeAlD
Ponatinib—KDR—head—germ cell cancer	0.00014	0.00188	CbGeAlD
Ponatinib—KIT—spinal cord—germ cell cancer	0.000139	0.00187	CbGeAlD
Ponatinib—Stomatitis—Etoposide—germ cell cancer	0.000139	0.00175	CcSEcCtD
Ponatinib—Jaundice—Etoposide—germ cell cancer	0.000139	0.00175	CcSEcCtD
Ponatinib—ABCG2—trigeminal ganglion—germ cell cancer	0.000139	0.00187	CbGeAlD
Ponatinib—Decreased appetite—Vinblastine—germ cell cancer	0.000139	0.00174	CcSEcCtD
Ponatinib—Ecchymosis—Methotrexate—germ cell cancer	0.000138	0.00173	CcSEcCtD
Ponatinib—PDGFRA—cerebellum—germ cell cancer	0.000138	0.00186	CbGeAlD
Ponatinib—Leukopenia—Dactinomycin—germ cell cancer	0.000138	0.00173	CcSEcCtD
Ponatinib—Connective tissue disorder—Cisplatin—germ cell cancer	0.000137	0.00172	CcSEcCtD
Ponatinib—Pain—Vinblastine—germ cell cancer	0.000137	0.00171	CcSEcCtD
Ponatinib—Constipation—Vinblastine—germ cell cancer	0.000137	0.00171	CcSEcCtD
Ponatinib—ABL1—medulla oblongata—germ cell cancer	0.000136	0.00183	CbGeAlD
Ponatinib—RET—brain—germ cell cancer	0.000136	0.00183	CbGeAlD
Ponatinib—SRC—cerebellum—germ cell cancer	0.000135	0.00182	CbGeAlD
Ponatinib—Hepatobiliary disease—Etoposide—germ cell cancer	0.000135	0.00169	CcSEcCtD
Ponatinib—Oedema—Bleomycin—germ cell cancer	0.000135	0.00169	CcSEcCtD
Ponatinib—KDR—testis—germ cell cancer	0.000135	0.00182	CbGeAlD
Ponatinib—Visual impairment—Cisplatin—germ cell cancer	0.000135	0.00169	CcSEcCtD
Ponatinib—KIT—female gonad—germ cell cancer	0.000135	0.00181	CbGeAlD
Ponatinib—Infection—Bleomycin—germ cell cancer	0.000134	0.00168	CcSEcCtD
Ponatinib—Vision blurred—Ifosfamide—germ cell cancer	0.000133	0.00167	CcSEcCtD
Ponatinib—Sepsis—Methotrexate—germ cell cancer	0.000133	0.00166	CcSEcCtD
Ponatinib—Thrombocytopenia—Bleomycin—germ cell cancer	0.000132	0.00166	CcSEcCtD
Ponatinib—RET—lymph node—germ cell cancer	0.000131	0.00177	CbGeAlD
Ponatinib—LCK—lymph node—germ cell cancer	0.000131	0.00177	CbGeAlD
Ponatinib—Myalgia—Dactinomycin—germ cell cancer	0.000131	0.00165	CcSEcCtD
Ponatinib—Eye disorder—Cisplatin—germ cell cancer	0.000131	0.00164	CcSEcCtD
Ponatinib—Gastrointestinal pain—Vinblastine—germ cell cancer	0.000131	0.00164	CcSEcCtD
Ponatinib—Anaemia—Ifosfamide—germ cell cancer	0.000131	0.00164	CcSEcCtD
Ponatinib—Flushing—Cisplatin—germ cell cancer	0.00013	0.00163	CcSEcCtD
Ponatinib—Cardiac disorder—Cisplatin—germ cell cancer	0.00013	0.00163	CcSEcCtD
Ponatinib—FGFR2—brain—germ cell cancer	0.000129	0.00174	CbGeAlD
Ponatinib—Hypoaesthesia—Etoposide—germ cell cancer	0.000127	0.0016	CcSEcCtD
Ponatinib—Leukopenia—Ifosfamide—germ cell cancer	0.000126	0.00159	CcSEcCtD
Ponatinib—Abdominal pain—Vinblastine—germ cell cancer	0.000126	0.00158	CcSEcCtD
Ponatinib—Mediastinal disorder—Cisplatin—germ cell cancer	0.000126	0.00158	CcSEcCtD
Ponatinib—Oedema—Dactinomycin—germ cell cancer	0.000126	0.00158	CcSEcCtD
Ponatinib—ABL1—adrenal gland—germ cell cancer	0.000126	0.00169	CbGeAlD
Ponatinib—KIT—endocrine gland—germ cell cancer	0.000125	0.00169	CbGeAlD
Ponatinib—Infection—Dactinomycin—germ cell cancer	0.000125	0.00157	CcSEcCtD
Ponatinib—Arrhythmia—Cisplatin—germ cell cancer	0.000125	0.00157	CcSEcCtD
Ponatinib—KDR—cerebellum—germ cell cancer	0.000125	0.00168	CbGeAlD
Ponatinib—ABL1—midbrain—germ cell cancer	0.000124	0.00167	CbGeAlD
Ponatinib—TEK—brain—germ cell cancer	0.000124	0.00167	CbGeAlD
Ponatinib—KIT—head—germ cell cancer	0.000124	0.00167	CbGeAlD
Ponatinib—Alopecia—Cisplatin—germ cell cancer	0.000124	0.00155	CcSEcCtD
Ponatinib—Cough—Ifosfamide—germ cell cancer	0.000123	0.00155	CcSEcCtD
Ponatinib—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000123	0.00154	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000123	0.00154	CcSEcCtD
Ponatinib—Hypertension—Ifosfamide—germ cell cancer	0.000122	0.00153	CcSEcCtD
Ponatinib—Malnutrition—Cisplatin—germ cell cancer	0.000122	0.00153	CcSEcCtD
Ponatinib—Erythema—Cisplatin—germ cell cancer	0.000122	0.00153	CcSEcCtD
Ponatinib—ABL1—bone marrow—germ cell cancer	0.000122	0.00164	CbGeAlD
Ponatinib—ABL1—spinal cord—germ cell cancer	0.000121	0.00163	CbGeAlD
Ponatinib—Paraesthesia—Bleomycin—germ cell cancer	0.000121	0.00152	CcSEcCtD
Ponatinib—Dyspnoea—Bleomycin—germ cell cancer	0.00012	0.00151	CcSEcCtD
Ponatinib—Arthralgia—Ifosfamide—germ cell cancer	0.00012	0.00151	CcSEcCtD
Ponatinib—Myalgia—Ifosfamide—germ cell cancer	0.00012	0.00151	CcSEcCtD
Ponatinib—Eye disorder—Etoposide—germ cell cancer	0.00012	0.0015	CcSEcCtD
Ponatinib—TEK—lymph node—germ cell cancer	0.00012	0.00161	CbGeAlD
Ponatinib—KIT—testis—germ cell cancer	0.000119	0.00161	CbGeAlD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000119	0.0015	CcSEcCtD
Ponatinib—Cardiac disorder—Etoposide—germ cell cancer	0.000119	0.00149	CcSEcCtD
Ponatinib—Flushing—Etoposide—germ cell cancer	0.000119	0.00149	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Methotrexate—germ cell cancer	0.000118	0.00148	CcSEcCtD
Ponatinib—ABL1—female gonad—germ cell cancer	0.000117	0.00158	CbGeAlD
Ponatinib—Decreased appetite—Bleomycin—germ cell cancer	0.000117	0.00147	CcSEcCtD
Ponatinib—Muscle spasms—Cisplatin—germ cell cancer	0.000117	0.00147	CcSEcCtD
Ponatinib—Angiopathy—Etoposide—germ cell cancer	0.000116	0.00146	CcSEcCtD
Ponatinib—Mediastinal disorder—Etoposide—germ cell cancer	0.000115	0.00145	CcSEcCtD
Ponatinib—Pain—Bleomycin—germ cell cancer	0.000115	0.00145	CcSEcCtD
Ponatinib—Oedema—Ifosfamide—germ cell cancer	0.000115	0.00145	CcSEcCtD
Ponatinib—Chills—Etoposide—germ cell cancer	0.000115	0.00144	CcSEcCtD
Ponatinib—Vision blurred—Cisplatin—germ cell cancer	0.000115	0.00144	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000115	0.00144	CcSEcCtD
Ponatinib—Asthenia—Vinblastine—germ cell cancer	0.000115	0.00144	CcSEcCtD
Ponatinib—Infection—Ifosfamide—germ cell cancer	0.000115	0.00144	CcSEcCtD
Ponatinib—Alopecia—Etoposide—germ cell cancer	0.000113	0.00142	CcSEcCtD
Ponatinib—Lethargy—Methotrexate—germ cell cancer	0.000113	0.00142	CcSEcCtD
Ponatinib—Cerebrovascular accident—Methotrexate—germ cell cancer	0.000113	0.00142	CcSEcCtD
Ponatinib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000113	0.00142	CcSEcCtD
Ponatinib—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000113	0.00142	CcSEcCtD
Ponatinib—Anaemia—Cisplatin—germ cell cancer	0.000113	0.00141	CcSEcCtD
Ponatinib—PDGFRA—brain—germ cell cancer	0.000112	0.00151	CbGeAlD
Ponatinib—Skin disorder—Ifosfamide—germ cell cancer	0.000112	0.0014	CcSEcCtD
Ponatinib—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000111	0.0014	CcSEcCtD
Ponatinib—ABCB1—blood vessel—germ cell cancer	0.000111	0.00149	CbGeAlD
Ponatinib—KIT—cerebellum—germ cell cancer	0.00011	0.00149	CbGeAlD
Ponatinib—SRC—brain—germ cell cancer	0.00011	0.00148	CbGeAlD
Ponatinib—Decreased appetite—Dactinomycin—germ cell cancer	0.000109	0.00137	CcSEcCtD
Ponatinib—Diarrhoea—Vinblastine—germ cell cancer	0.000109	0.00137	CcSEcCtD
Ponatinib—ABL1—endocrine gland—germ cell cancer	0.000109	0.00147	CbGeAlD
Ponatinib—ABCG2—telencephalon—germ cell cancer	0.000109	0.00147	CbGeAlD
Ponatinib—Leukopenia—Cisplatin—germ cell cancer	0.000109	0.00137	CcSEcCtD
Ponatinib—Fatigue—Dactinomycin—germ cell cancer	0.000108	0.00136	CcSEcCtD
Ponatinib—PDGFRA—lymph node—germ cell cancer	0.000108	0.00146	CbGeAlD
Ponatinib—Back pain—Etoposide—germ cell cancer	0.000108	0.00135	CcSEcCtD
Ponatinib—ABL1—head—germ cell cancer	0.000108	0.00145	CbGeAlD
Ponatinib—Pain—Dactinomycin—germ cell cancer	0.000108	0.00135	CcSEcCtD
Ponatinib—Muscle spasms—Etoposide—germ cell cancer	0.000107	0.00135	CcSEcCtD
Ponatinib—Body temperature increased—Bleomycin—germ cell cancer	0.000107	0.00134	CcSEcCtD
Ponatinib—SRC—lymph node—germ cell cancer	0.000106	0.00143	CbGeAlD
Ponatinib—Dizziness—Vinblastine—germ cell cancer	0.000106	0.00132	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000105	0.00132	CcSEcCtD
Ponatinib—ABL1—testis—germ cell cancer	0.000104	0.0014	CbGeAlD
Ponatinib—Myalgia—Cisplatin—germ cell cancer	0.000104	0.0013	CcSEcCtD
Ponatinib—Paraesthesia—Ifosfamide—germ cell cancer	0.000104	0.0013	CcSEcCtD
Ponatinib—ABCG2—decidua—germ cell cancer	0.000103	0.00139	CbGeAlD
Ponatinib—Anaemia—Etoposide—germ cell cancer	0.000103	0.00129	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000103	0.00129	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000103	0.00129	CcSEcCtD
Ponatinib—Dyspnoea—Ifosfamide—germ cell cancer	0.000103	0.00129	CcSEcCtD
Ponatinib—Vomiting—Vinblastine—germ cell cancer	0.000102	0.00127	CcSEcCtD
Ponatinib—KDR—brain—germ cell cancer	0.000101	0.00136	CbGeAlD
Ponatinib—Breast disorder—Methotrexate—germ cell cancer	0.0001	0.00126	CcSEcCtD
Ponatinib—Decreased appetite—Ifosfamide—germ cell cancer	0.0001	0.00126	CcSEcCtD
Ponatinib—Headache—Vinblastine—germ cell cancer	0.0001	0.00125	CcSEcCtD
Ponatinib—Leukopenia—Etoposide—germ cell cancer	9.98e-05	0.00125	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	9.95e-05	0.00125	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—germ cell cancer	9.94e-05	0.00125	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—germ cell cancer	9.94e-05	0.00125	CcSEcCtD
Ponatinib—Fatigue—Ifosfamide—germ cell cancer	9.94e-05	0.00125	CcSEcCtD
Ponatinib—Oedema—Cisplatin—germ cell cancer	9.94e-05	0.00125	CcSEcCtD
Ponatinib—Infection—Cisplatin—germ cell cancer	9.87e-05	0.00124	CcSEcCtD
Ponatinib—Constipation—Ifosfamide—germ cell cancer	9.86e-05	0.00124	CcSEcCtD
Ponatinib—Pain—Ifosfamide—germ cell cancer	9.86e-05	0.00124	CcSEcCtD
Ponatinib—KDR—lymph node—germ cell cancer	9.77e-05	0.00132	CbGeAlD
Ponatinib—Nervous system disorder—Cisplatin—germ cell cancer	9.75e-05	0.00122	CcSEcCtD
Ponatinib—Cough—Etoposide—germ cell cancer	9.73e-05	0.00122	CcSEcCtD
Ponatinib—Thrombocytopenia—Cisplatin—germ cell cancer	9.73e-05	0.00122	CcSEcCtD
Ponatinib—Asthenia—Bleomycin—germ cell cancer	9.68e-05	0.00121	CcSEcCtD
Ponatinib—Skin disorder—Cisplatin—germ cell cancer	9.65e-05	0.00121	CcSEcCtD
Ponatinib—Hypertension—Etoposide—germ cell cancer	9.63e-05	0.00121	CcSEcCtD
Ponatinib—ABL1—cerebellum—germ cell cancer	9.61e-05	0.00129	CbGeAlD
Ponatinib—Hyperhidrosis—Cisplatin—germ cell cancer	9.61e-05	0.00121	CcSEcCtD
Ponatinib—Pruritus—Bleomycin—germ cell cancer	9.54e-05	0.0012	CcSEcCtD
Ponatinib—Nausea—Vinblastine—germ cell cancer	9.49e-05	0.00119	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	9.43e-05	0.00118	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ifosfamide—germ cell cancer	9.43e-05	0.00118	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—germ cell cancer	9.4e-05	0.00118	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—germ cell cancer	9.19e-05	0.00115	CcSEcCtD
Ponatinib—CYP2C8—pituitary gland—germ cell cancer	9.13e-05	0.00123	CbGeAlD
Ponatinib—Abdominal pain—Ifosfamide—germ cell cancer	9.11e-05	0.00114	CcSEcCtD
Ponatinib—Body temperature increased—Ifosfamide—germ cell cancer	9.11e-05	0.00114	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—germ cell cancer	9.11e-05	0.00114	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	9.05e-05	0.00114	CcSEcCtD
Ponatinib—Infection—Etoposide—germ cell cancer	9.04e-05	0.00113	CcSEcCtD
Ponatinib—ABCG2—uterus—germ cell cancer	9.04e-05	0.00122	CbGeAlD
Ponatinib—Asthenia—Dactinomycin—germ cell cancer	9.02e-05	0.00113	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—germ cell cancer	8.97e-05	0.00112	CcSEcCtD
Ponatinib—KIT—brain—germ cell cancer	8.96e-05	0.00121	CbGeAlD
Ponatinib—Paraesthesia—Cisplatin—germ cell cancer	8.92e-05	0.00112	CcSEcCtD
Ponatinib—Thrombocytopenia—Etoposide—germ cell cancer	8.91e-05	0.00112	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—germ cell cancer	8.91e-05	0.00112	CcSEcCtD
Ponatinib—ABCG2—pituitary gland—germ cell cancer	8.88e-05	0.0012	CbGeAlD
Ponatinib—Dyspnoea—Cisplatin—germ cell cancer	8.86e-05	0.00111	CcSEcCtD
Ponatinib—Skin disorder—Etoposide—germ cell cancer	8.84e-05	0.00111	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—germ cell cancer	8.83e-05	0.00111	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—germ cell cancer	8.8e-05	0.0011	CcSEcCtD
Ponatinib—KIT—lymph node—germ cell cancer	8.66e-05	0.00117	CbGeAlD
Ponatinib—Decreased appetite—Cisplatin—germ cell cancer	8.64e-05	0.00108	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—germ cell cancer	8.61e-05	0.00108	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—germ cell cancer	8.6e-05	0.00108	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—germ cell cancer	8.58e-05	0.00108	CcSEcCtD
Ponatinib—Vomiting—Bleomycin—germ cell cancer	8.58e-05	0.00108	CcSEcCtD
Ponatinib—ABCG2—medulla oblongata—germ cell cancer	8.57e-05	0.00115	CbGeAlD
Ponatinib—Infestation—Methotrexate—germ cell cancer	8.55e-05	0.00107	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—germ cell cancer	8.55e-05	0.00107	CcSEcCtD
Ponatinib—Rash—Bleomycin—germ cell cancer	8.5e-05	0.00107	CcSEcCtD
Ponatinib—Pain—Cisplatin—germ cell cancer	8.5e-05	0.00107	CcSEcCtD
Ponatinib—Dermatitis—Bleomycin—germ cell cancer	8.5e-05	0.00107	CcSEcCtD
Ponatinib—CYP2D6—brainstem—germ cell cancer	8.42e-05	0.00113	CbGeAlD
Ponatinib—Stomatitis—Methotrexate—germ cell cancer	8.33e-05	0.00105	CcSEcCtD
Ponatinib—Asthenia—Ifosfamide—germ cell cancer	8.27e-05	0.00104	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—germ cell cancer	8.17e-05	0.00103	CcSEcCtD
Ponatinib—Pruritus—Ifosfamide—germ cell cancer	8.16e-05	0.00102	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—germ cell cancer	8.12e-05	0.00102	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—germ cell cancer	8.09e-05	0.00101	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—germ cell cancer	8.06e-05	0.00101	CcSEcCtD
Ponatinib—Nausea—Bleomycin—germ cell cancer	8.01e-05	0.001	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—germ cell cancer	8e-05	0.001	CcSEcCtD
Ponatinib—ABCG2—adrenal gland—germ cell cancer	7.93e-05	0.00107	CbGeAlD
Ponatinib—Rash—Dactinomycin—germ cell cancer	7.93e-05	0.000995	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—germ cell cancer	7.91e-05	0.000993	CcSEcCtD
Ponatinib—Diarrhoea—Ifosfamide—germ cell cancer	7.89e-05	0.000989	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—germ cell cancer	7.86e-05	0.000986	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—germ cell cancer	7.86e-05	0.000985	CcSEcCtD
Ponatinib—Fatigue—Etoposide—germ cell cancer	7.85e-05	0.000985	CcSEcCtD
Ponatinib—ABCG2—midbrain—germ cell cancer	7.83e-05	0.00105	CbGeAlD
Ponatinib—ABL1—brain—germ cell cancer	7.8e-05	0.00105	CbGeAlD
Ponatinib—Pain—Etoposide—germ cell cancer	7.79e-05	0.000977	CcSEcCtD
Ponatinib—Constipation—Etoposide—germ cell cancer	7.79e-05	0.000977	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—germ cell cancer	7.71e-05	0.000968	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—germ cell cancer	7.68e-05	0.000963	CcSEcCtD
Ponatinib—ABCG2—bone marrow—germ cell cancer	7.67e-05	0.00103	CbGeAlD
Ponatinib—ABCG2—spinal cord—germ cell cancer	7.64e-05	0.00103	CbGeAlD
Ponatinib—Dizziness—Ifosfamide—germ cell cancer	7.62e-05	0.000956	CcSEcCtD
Ponatinib—ABL1—lymph node—germ cell cancer	7.54e-05	0.00102	CbGeAlD
Ponatinib—CYP2D6—telencephalon—germ cell cancer	7.48e-05	0.00101	CbGeAlD
Ponatinib—Nausea—Dactinomycin—germ cell cancer	7.47e-05	0.000937	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—germ cell cancer	7.44e-05	0.000934	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—germ cell cancer	7.4e-05	0.000928	CcSEcCtD
Ponatinib—ABCG2—female gonad—germ cell cancer	7.4e-05	0.000996	CbGeAlD
Ponatinib—Vomiting—Ifosfamide—germ cell cancer	7.33e-05	0.000919	CcSEcCtD
Ponatinib—Rash—Ifosfamide—germ cell cancer	7.27e-05	0.000912	CcSEcCtD
Ponatinib—Dermatitis—Ifosfamide—germ cell cancer	7.26e-05	0.000911	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—germ cell cancer	7.2e-05	0.000903	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—germ cell cancer	7.2e-05	0.000903	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—germ cell cancer	7.17e-05	0.0009	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—germ cell cancer	7.13e-05	0.000894	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—germ cell cancer	7.12e-05	0.000894	CcSEcCtD
Ponatinib—CYP2C8—endocrine gland—germ cell cancer	7.07e-05	0.000953	CbGeAlD
Ponatinib—Angiopathy—Methotrexate—germ cell cancer	6.96e-05	0.000874	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—germ cell cancer	6.92e-05	0.000868	CcSEcCtD
Ponatinib—Chills—Methotrexate—germ cell cancer	6.89e-05	0.000864	CcSEcCtD
Ponatinib—CYP3A5—female gonad—germ cell cancer	6.87e-05	0.000925	CbGeAlD
Ponatinib—ABCB1—trigeminal ganglion—germ cell cancer	6.85e-05	0.000922	CbGeAlD
Ponatinib—Nausea—Ifosfamide—germ cell cancer	6.85e-05	0.000859	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—germ cell cancer	6.8e-05	0.000853	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—germ cell cancer	6.78e-05	0.000851	CcSEcCtD
Ponatinib—CYP2C8—testis—germ cell cancer	6.75e-05	0.000909	CbGeAlD
Ponatinib—Mental disorder—Methotrexate—germ cell cancer	6.72e-05	0.000844	CcSEcCtD
Ponatinib—Erythema—Methotrexate—germ cell cancer	6.68e-05	0.000838	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—germ cell cancer	6.68e-05	0.000838	CcSEcCtD
Ponatinib—ABCB1—embryo—germ cell cancer	6.61e-05	0.00089	CbGeAlD
Ponatinib—ABCG2—testis—germ cell cancer	6.56e-05	0.000883	CbGeAlD
Ponatinib—Asthenia—Etoposide—germ cell cancer	6.53e-05	0.000819	CcSEcCtD
Ponatinib—Back pain—Methotrexate—germ cell cancer	6.46e-05	0.000811	CcSEcCtD
Ponatinib—Pruritus—Etoposide—germ cell cancer	6.44e-05	0.000808	CcSEcCtD
Ponatinib—CYP3A5—endocrine gland—germ cell cancer	6.38e-05	0.00086	CbGeAlD
Ponatinib—Vomiting—Cisplatin—germ cell cancer	6.32e-05	0.000793	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—germ cell cancer	6.3e-05	0.00079	CcSEcCtD
Ponatinib—Rash—Cisplatin—germ cell cancer	6.27e-05	0.000786	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—germ cell cancer	6.26e-05	0.000785	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—germ cell cancer	6.23e-05	0.000781	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—germ cell cancer	6.18e-05	0.000775	CcSEcCtD
Ponatinib—ABCG2—cerebellum—germ cell cancer	6.06e-05	0.000816	CbGeAlD
Ponatinib—Dizziness—Etoposide—germ cell cancer	6.02e-05	0.000755	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—germ cell cancer	5.98e-05	0.00075	CcSEcCtD
Ponatinib—Nausea—Cisplatin—germ cell cancer	5.9e-05	0.00074	CcSEcCtD
Ponatinib—ABCB1—retina—germ cell cancer	5.85e-05	0.000787	CbGeAlD
Ponatinib—Cough—Methotrexate—germ cell cancer	5.83e-05	0.000731	CcSEcCtD
Ponatinib—Vomiting—Etoposide—germ cell cancer	5.79e-05	0.000726	CcSEcCtD
Ponatinib—Rash—Etoposide—germ cell cancer	5.74e-05	0.00072	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—germ cell cancer	5.73e-05	0.000719	CcSEcCtD
Ponatinib—Headache—Etoposide—germ cell cancer	5.7e-05	0.000715	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—germ cell cancer	5.69e-05	0.000714	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—germ cell cancer	5.69e-05	0.000714	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	5.65e-05	0.000709	CcSEcCtD
Ponatinib—Infection—Methotrexate—germ cell cancer	5.42e-05	0.00068	CcSEcCtD
Ponatinib—Nausea—Etoposide—germ cell cancer	5.41e-05	0.000678	CcSEcCtD
Ponatinib—ABCB1—telencephalon—germ cell cancer	5.38e-05	0.000724	CbGeAlD
Ponatinib—Nervous system disorder—Methotrexate—germ cell cancer	5.35e-05	0.000671	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—germ cell cancer	5.34e-05	0.00067	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—germ cell cancer	5.3e-05	0.000664	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—germ cell cancer	5.27e-05	0.000661	CcSEcCtD
Ponatinib—ABCB1—decidua—germ cell cancer	5.1e-05	0.000686	CbGeAlD
Ponatinib—CYP2D6—female gonad—germ cell cancer	5.07e-05	0.000683	CbGeAlD
Ponatinib—CYP2C8—brain—germ cell cancer	5.06e-05	0.000682	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	4.97e-05	0.000623	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—germ cell cancer	4.93e-05	0.000619	CcSEcCtD
Ponatinib—ABCG2—brain—germ cell cancer	4.92e-05	0.000663	CbGeAlD
Ponatinib—Paraesthesia—Methotrexate—germ cell cancer	4.9e-05	0.000614	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—germ cell cancer	4.86e-05	0.00061	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—germ cell cancer	4.8e-05	0.000602	CcSEcCtD
Ponatinib—CYP3A4—endocrine gland—germ cell cancer	4.79e-05	0.000645	CbGeAlD
Ponatinib—ABCG2—lymph node—germ cell cancer	4.75e-05	0.00064	CbGeAlD
Ponatinib—Decreased appetite—Methotrexate—germ cell cancer	4.74e-05	0.000595	CcSEcCtD
Ponatinib—CYP2D6—endocrine gland—germ cell cancer	4.71e-05	0.000635	CbGeAlD
Ponatinib—Gastrointestinal disorder—Methotrexate—germ cell cancer	4.71e-05	0.000591	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—germ cell cancer	4.7e-05	0.00059	CcSEcCtD
Ponatinib—Pain—Methotrexate—germ cell cancer	4.66e-05	0.000585	CcSEcCtD
Ponatinib—CYP2D6—head—germ cell cancer	4.65e-05	0.000627	CbGeAlD
Ponatinib—CYP2D6—testis—germ cell cancer	4.5e-05	0.000606	CbGeAlD
Ponatinib—ABCB1—gonad—germ cell cancer	4.49e-05	0.000604	CbGeAlD
Ponatinib—Gastrointestinal pain—Methotrexate—germ cell cancer	4.46e-05	0.000559	CcSEcCtD
Ponatinib—ABCB1—uterus—germ cell cancer	4.46e-05	0.0006	CbGeAlD
Ponatinib—ABCB1—pituitary gland—germ cell cancer	4.38e-05	0.00059	CbGeAlD
Ponatinib—Body temperature increased—Methotrexate—germ cell cancer	4.31e-05	0.000541	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—germ cell cancer	4.31e-05	0.000541	CcSEcCtD
Ponatinib—ABCB1—medulla oblongata—germ cell cancer	4.22e-05	0.000569	CbGeAlD
Ponatinib—CYP2D6—cerebellum—germ cell cancer	4.15e-05	0.000559	CbGeAlD
Ponatinib—Asthenia—Methotrexate—germ cell cancer	3.91e-05	0.000491	CcSEcCtD
Ponatinib—ABCB1—adrenal gland—germ cell cancer	3.91e-05	0.000527	CbGeAlD
Ponatinib—ABCB1—midbrain—germ cell cancer	3.86e-05	0.00052	CbGeAlD
Ponatinib—Pruritus—Methotrexate—germ cell cancer	3.86e-05	0.000484	CcSEcCtD
Ponatinib—ABCB1—bone marrow—germ cell cancer	3.78e-05	0.00051	CbGeAlD
Ponatinib—ABCB1—spinal cord—germ cell cancer	3.77e-05	0.000507	CbGeAlD
Ponatinib—Diarrhoea—Methotrexate—germ cell cancer	3.73e-05	0.000468	CcSEcCtD
Ponatinib—ABCB1—female gonad—germ cell cancer	3.65e-05	0.000491	CbGeAlD
Ponatinib—Dizziness—Methotrexate—germ cell cancer	3.61e-05	0.000452	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—germ cell cancer	3.47e-05	0.000435	CcSEcCtD
Ponatinib—Rash—Methotrexate—germ cell cancer	3.44e-05	0.000431	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—germ cell cancer	3.44e-05	0.000431	CcSEcCtD
Ponatinib—Headache—Methotrexate—germ cell cancer	3.42e-05	0.000429	CcSEcCtD
Ponatinib—ABCB1—endocrine gland—germ cell cancer	3.39e-05	0.000457	CbGeAlD
Ponatinib—CYP2D6—brain—germ cell cancer	3.37e-05	0.000454	CbGeAlD
Ponatinib—ABCB1—head—germ cell cancer	3.35e-05	0.000451	CbGeAlD
Ponatinib—Nausea—Methotrexate—germ cell cancer	3.24e-05	0.000406	CcSEcCtD
Ponatinib—ABCB1—testis—germ cell cancer	3.23e-05	0.000436	CbGeAlD
Ponatinib—ABCB1—cerebellum—germ cell cancer	2.99e-05	0.000402	CbGeAlD
Ponatinib—ABCB1—brain—germ cell cancer	2.43e-05	0.000327	CbGeAlD
Ponatinib—ABCB1—lymph node—germ cell cancer	2.34e-05	0.000316	CbGeAlD
Ponatinib—FGFR2—Disease—KITLG—germ cell cancer	1.07e-05	0.000103	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KIT—germ cell cancer	1.06e-05	0.000103	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—OXT—germ cell cancer	1.06e-05	0.000103	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AVP—germ cell cancer	1.06e-05	0.000103	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	1.06e-05	0.000102	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KIT—germ cell cancer	1.06e-05	0.000102	CbGpPWpGaD
Ponatinib—SRC—BDNF signaling pathway—HRAS—germ cell cancer	1.06e-05	0.000102	CbGpPWpGaD
Ponatinib—KIT—Disease—KITLG—germ cell cancer	1.05e-05	0.000101	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—OXT—germ cell cancer	1.04e-05	0.000101	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—H2AFZ—germ cell cancer	1.03e-05	9.94e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—HRAS—germ cell cancer	1.02e-05	9.92e-05	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	1.01e-05	9.78e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR in disease—HRAS—germ cell cancer	1.01e-05	9.78e-05	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—HRAS—germ cell cancer	1.01e-05	9.78e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—HRAS—germ cell cancer	1.01e-05	9.74e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR—HRAS—germ cell cancer	1e-05	9.7e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KIT—germ cell cancer	1e-05	9.69e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KITLG—germ cell cancer	9.93e-06	9.61e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—HRAS—germ cell cancer	9.93e-06	9.61e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—OXT—germ cell cancer	9.92e-06	9.6e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KITLG—germ cell cancer	9.9e-06	9.59e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—FGFR3—germ cell cancer	9.9e-06	9.58e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—OXT—germ cell cancer	9.89e-06	9.57e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CRABP1—germ cell cancer	9.89e-06	9.57e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—HRAS—germ cell cancer	9.88e-06	9.57e-05	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—HRAS—germ cell cancer	9.65e-06	9.34e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR—HRAS—germ cell cancer	9.6e-06	9.3e-05	CbGpPWpGaD
Ponatinib—SRC—EGF/EGFR Signaling Pathway—HRAS—germ cell cancer	9.6e-06	9.3e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—HRAS—germ cell cancer	9.56e-06	9.25e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—HRAS—germ cell cancer	9.55e-06	9.24e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—HRAS—germ cell cancer	9.52e-06	9.22e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—FGFR3—germ cell cancer	9.5e-06	9.2e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KITLG—germ cell cancer	9.46e-06	9.16e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KITLG—germ cell cancer	9.45e-06	9.15e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—FGF4—germ cell cancer	9.44e-06	9.14e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KITLG—germ cell cancer	9.42e-06	9.12e-05	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—HRAS—germ cell cancer	9.35e-06	9.05e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AVP—germ cell cancer	9.24e-06	8.94e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KIT—germ cell cancer	9.09e-06	8.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FGF4—germ cell cancer	9.08e-06	8.79e-05	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	8.95e-06	8.67e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—HRAS—germ cell cancer	8.95e-06	8.66e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FGF4—germ cell cancer	8.92e-06	8.63e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—HRAS—germ cell cancer	8.87e-06	8.58e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SLC2A3—germ cell cancer	8.82e-06	8.54e-05	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	8.8e-06	8.52e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—HRAS—germ cell cancer	8.79e-06	8.51e-05	CbGpPWpGaD
Ponatinib—BCR—Disease—HRAS—germ cell cancer	8.76e-06	8.48e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—FGFR3—germ cell cancer	8.76e-06	8.48e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—HRAS—germ cell cancer	8.75e-06	8.47e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KIT—germ cell cancer	8.73e-06	8.45e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—OXT—germ cell cancer	8.72e-06	8.45e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—FGF4—germ cell cancer	8.72e-06	8.44e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SLC22A3—germ cell cancer	8.69e-06	8.41e-05	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—HRAS—germ cell cancer	8.64e-06	8.36e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—FGFR3—germ cell cancer	8.58e-06	8.3e-05	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—HRAS—germ cell cancer	8.54e-06	8.27e-05	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—HRAS—germ cell cancer	8.49e-06	8.22e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FGF4—germ cell cancer	8.46e-06	8.19e-05	CbGpPWpGaD
Ponatinib—SRC—Focal Adhesion—HRAS—germ cell cancer	8.45e-06	8.18e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FGF4—germ cell cancer	8.44e-06	8.17e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—FGFR3—germ cell cancer	8.42e-06	8.15e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—FGFR3—germ cell cancer	8.41e-06	8.14e-05	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—HRAS—germ cell cancer	8.38e-06	8.11e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—FGF4—germ cell cancer	8.36e-06	8.09e-05	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—HRAS—germ cell cancer	8.16e-06	7.9e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—H2AFZ—germ cell cancer	8.11e-06	7.85e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KIT—germ cell cancer	8.04e-06	7.79e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—FGFR3—germ cell cancer	7.99e-06	7.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—FGFR3—germ cell cancer	7.97e-06	7.72e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—H2AFZ—germ cell cancer	7.96e-06	7.71e-05	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	7.92e-06	7.67e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—FGFR3—germ cell cancer	7.92e-06	7.66e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KIT—germ cell cancer	7.87e-06	7.62e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—MYC—germ cell cancer	7.86e-06	7.61e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—MYC—germ cell cancer	7.81e-06	7.57e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—H2AFZ—germ cell cancer	7.78e-06	7.53e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—FGFR3—germ cell cancer	7.78e-06	7.53e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KITLG—germ cell cancer	7.76e-06	7.51e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KIT—germ cell cancer	7.72e-06	7.48e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—FGF4—germ cell cancer	7.72e-06	7.47e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC2A3—germ cell cancer	7.64e-06	7.4e-05	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—HRAS—germ cell cancer	7.6e-06	7.36e-05	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—HRAS—germ cell cancer	7.57e-06	7.32e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—H2AFZ—germ cell cancer	7.56e-06	7.32e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—H2AFZ—germ cell cancer	7.54e-06	7.3e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC22A3—germ cell cancer	7.53e-06	7.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KITLG—germ cell cancer	7.46e-06	7.22e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FGF4—germ cell cancer	7.45e-06	7.21e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KIT—germ cell cancer	7.4e-06	7.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—FGFR3—germ cell cancer	7.38e-06	7.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—FGFR3—germ cell cancer	7.36e-06	7.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KIT—germ cell cancer	7.34e-06	7.1e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KITLG—germ cell cancer	7.33e-06	7.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KIT—germ cell cancer	7.32e-06	7.09e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AVP—germ cell cancer	7.29e-06	7.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KIT—germ cell cancer	7.27e-06	7.04e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AVP—germ cell cancer	7.16e-06	6.93e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KITLG—germ cell cancer	7.16e-06	6.93e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—OXT—germ cell cancer	7.15e-06	6.92e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CRABP1—germ cell cancer	7.08e-06	6.86e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—FGFR3—germ cell cancer	7.03e-06	6.81e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FGFR3—germ cell cancer	7.02e-06	6.8e-05	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—HRAS—germ cell cancer	7e-06	6.78e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—FGFR3—germ cell cancer	7e-06	6.78e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KITLG—germ cell cancer	6.95e-06	6.73e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KITLG—germ cell cancer	6.94e-06	6.71e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—H2AFZ—germ cell cancer	6.89e-06	6.67e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—HRAS—germ cell cancer	6.88e-06	6.66e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KITLG—germ cell cancer	6.87e-06	6.65e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AVP—germ cell cancer	6.8e-06	6.58e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AVP—germ cell cancer	6.78e-06	6.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KIT—germ cell cancer	6.78e-06	6.56e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KIT—germ cell cancer	6.76e-06	6.54e-05	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—HRAS—germ cell cancer	6.69e-06	6.47e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC2A3—germ cell cancer	6.66e-06	6.44e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—H2AFZ—germ cell cancer	6.65e-06	6.44e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC22A3—germ cell cancer	6.56e-06	6.35e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	6.55e-06	6.35e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KIT—germ cell cancer	6.46e-06	6.25e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KIT—germ cell cancer	6.45e-06	6.24e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KIT—germ cell cancer	6.43e-06	6.22e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—germ cell cancer	6.42e-06	6.21e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	6.34e-06	6.14e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KITLG—germ cell cancer	6.34e-06	6.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—OXT—germ cell cancer	6.33e-06	6.13e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC2A3—germ cell cancer	6.27e-06	6.07e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC22A3—germ cell cancer	6.18e-06	5.98e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—HRAS—germ cell cancer	6.18e-06	5.98e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—HRAS—germ cell cancer	6.17e-06	5.97e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—HRAS—germ cell cancer	6.14e-06	5.94e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CRABP1—germ cell cancer	6.14e-06	5.94e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KITLG—germ cell cancer	6.12e-06	5.92e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGF4—germ cell cancer	6.1e-06	5.91e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—HRAS—germ cell cancer	6.09e-06	5.9e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AVP—germ cell cancer	5.98e-06	5.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—HRAS—germ cell cancer	5.84e-06	5.66e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—MYC—germ cell cancer	5.82e-06	5.63e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—FGFR3—germ cell cancer	5.76e-06	5.58e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HRAS—germ cell cancer	5.74e-06	5.55e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HRAS—germ cell cancer	5.61e-06	5.43e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—germ cell cancer	5.56e-06	5.39e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FGFR3—germ cell cancer	5.54e-06	5.37e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—germ cell cancer	5.54e-06	5.36e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—HRAS—germ cell cancer	5.52e-06	5.34e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HRAS—germ cell cancer	5.51e-06	5.33e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MYC—germ cell cancer	5.51e-06	5.33e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—H2AFZ—germ cell cancer	5.45e-06	5.28e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FGFR3—germ cell cancer	5.45e-06	5.27e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—HRAS—germ cell cancer	5.45e-06	5.27e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—HRAS—germ cell cancer	5.43e-06	5.26e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—HRAS—germ cell cancer	5.42e-06	5.25e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGF4—germ cell cancer	5.4e-06	5.23e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—HRAS—germ cell cancer	5.4e-06	5.23e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CRABP1—germ cell cancer	5.35e-06	5.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—FGFR3—germ cell cancer	5.32e-06	5.15e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—HRAS—germ cell cancer	5.32e-06	5.15e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—HRAS—germ cell cancer	5.3e-06	5.13e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KIT—germ cell cancer	5.29e-06	5.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HRAS—germ cell cancer	5.23e-06	5.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HRAS—germ cell cancer	5.22e-06	5.05e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	5.21e-06	5.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FGFR3—germ cell cancer	5.17e-06	5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FGFR3—germ cell cancer	5.15e-06	4.99e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—FGFR3—germ cell cancer	5.1e-06	4.94e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KIT—germ cell cancer	5.09e-06	4.93e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CRABP1—germ cell cancer	5.04e-06	4.88e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KITLG—germ cell cancer	5.01e-06	4.85e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HRAS—germ cell cancer	4.95e-06	4.79e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AVP—germ cell cancer	4.9e-06	4.74e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KIT—germ cell cancer	4.89e-06	4.73e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—H2AFZ—germ cell cancer	4.83e-06	4.67e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HRAS—germ cell cancer	4.79e-06	4.64e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HRAS—germ cell cancer	4.77e-06	4.62e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KIT—germ cell cancer	4.74e-06	4.59e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KIT—germ cell cancer	4.73e-06	4.58e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—FGFR3—germ cell cancer	4.71e-06	4.56e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KIT—germ cell cancer	4.69e-06	4.54e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—germ cell cancer	4.6e-06	4.45e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—germ cell cancer	4.57e-06	4.42e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—germ cell cancer	4.56e-06	4.42e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FGFR3—germ cell cancer	4.55e-06	4.4e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—germ cell cancer	4.52e-06	4.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KITLG—germ cell cancer	4.44e-06	4.3e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—germ cell cancer	4.36e-06	4.22e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AVP—germ cell cancer	4.34e-06	4.2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KIT—germ cell cancer	4.33e-06	4.19e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—germ cell cancer	4.32e-06	4.19e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KIT—germ cell cancer	4.17e-06	4.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	4.1e-06	3.97e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—germ cell cancer	4.07e-06	3.94e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	4.04e-06	3.91e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—germ cell cancer	4.04e-06	3.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—germ cell cancer	4e-06	3.87e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—germ cell cancer	3.94e-06	3.81e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—germ cell cancer	3.93e-06	3.8e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—germ cell cancer	3.93e-06	3.8e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—germ cell cancer	3.86e-06	3.74e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—germ cell cancer	3.77e-06	3.65e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—germ cell cancer	3.73e-06	3.61e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGFR3—germ cell cancer	3.73e-06	3.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—germ cell cancer	3.72e-06	3.6e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—germ cell cancer	3.55e-06	3.43e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—germ cell cancer	3.48e-06	3.37e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—germ cell cancer	3.42e-06	3.31e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—germ cell cancer	3.4e-06	3.29e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—germ cell cancer	3.34e-06	3.24e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—germ cell cancer	3.34e-06	3.24e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—germ cell cancer	3.34e-06	3.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGFR3—germ cell cancer	3.3e-06	3.19e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CRABP1—germ cell cancer	3.29e-06	3.19e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—germ cell cancer	3.2e-06	3.1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—germ cell cancer	3.17e-06	3.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—germ cell cancer	3.16e-06	3.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—germ cell cancer	3.14e-06	3.04e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—germ cell cancer	3.09e-06	2.99e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—germ cell cancer	3.03e-06	2.93e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—germ cell cancer	2.93e-06	2.83e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—germ cell cancer	2.92e-06	2.83e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—germ cell cancer	2.91e-06	2.82e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—germ cell cancer	2.8e-06	2.71e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—germ cell cancer	2.79e-06	2.7e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—germ cell cancer	2.79e-06	2.7e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—germ cell cancer	2.78e-06	2.69e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—germ cell cancer	2.75e-06	2.66e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—germ cell cancer	2.69e-06	2.6e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—germ cell cancer	2.61e-06	2.53e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—germ cell cancer	2.6e-06	2.52e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—germ cell cancer	2.38e-06	2.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—germ cell cancer	2.3e-06	2.23e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—germ cell cancer	2.3e-06	2.22e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—germ cell cancer	2.29e-06	2.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—germ cell cancer	2.26e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—germ cell cancer	2.2e-06	2.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—germ cell cancer	2.16e-06	2.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—germ cell cancer	2.14e-06	2.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—germ cell cancer	2.14e-06	2.07e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—germ cell cancer	2.11e-06	2.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—germ cell cancer	2.05e-06	1.99e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—germ cell cancer	2.05e-06	1.98e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—germ cell cancer	2.02e-06	1.96e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—germ cell cancer	1.89e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—germ cell cancer	1.88e-06	1.82e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—germ cell cancer	1.87e-06	1.81e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—germ cell cancer	1.8e-06	1.75e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—germ cell cancer	1.67e-06	1.61e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—germ cell cancer	1.55e-06	1.5e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—germ cell cancer	1.48e-06	1.43e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—germ cell cancer	1.37e-06	1.33e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—germ cell cancer	1.31e-06	1.27e-05	CbGpPWpGaD
